FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667512> ?p ?o ?g. }

• W4385667512 endingPage "e08128cd" @default.
• W4385667512 startingPage "e08128cd" @default.
• W4385667512 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Ixazomib-lenalidomide and dexamethasone (IRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the pivotal Tourmaline MM-1 trial. Aims: We conducted an observational analysis of 81 RRMM patients (pts) treated with IRd between January 2017 and May 2021 in 18 Northern Italy centers, with the aim to evaluate efficacy and safety of IRd in real-life. Methods: The study comprises a retrospective phase (chart review of the period from ixazomib initiation to enrolment) followed by a 18-month prospective follow-up period. Results: At IRd initiation, 32% of pts were aged ≥75 (median age 72), 30% had an ECOG performance status ≥2, 54% of evaluable (64/81) pts carried high risk cytogenetic abnormalities (HRCA) [del17p and/or t(4;14) and/or t(14;16)] and/or 1q gain/amp], median number of prior lines of therapy was 2 (1-6) with 57% receiving ≥2 prior lines, 71% were exposed to lenalidomide, 24% were lenalidomide-refractory. Median time from diagnosis was 60 months. At the median of 31 months, 81% of the pts had discontinued treatment, mainly (62%) for progression. Main grade 3-4 adverse events (AEs) were neutropenia (11%) and thrombocytopenia (11%). Non-hematological grade 3-4 AEs were infections, venous thromboembolism, gastrointestinal toxicity, reported in 2 (2.5%), 3 (3.7%) and 4 (5%) pts respectively. Overall, the response rate was 53% (≥VGPR 32%). With a median follow up of 31 months, median PFS (mPFS) was 12 months, ranging from 21 months in pts receiving 1 prior line and 7.4 months in pts receiving >3 prior lines respectively. 1-year OS rate was 53%. By subgroup analysis, extended PFS was observed for pts aged ≥75 (mPFS 26.2 months), with 1 prior line of therapy (21 months), achieving at least a VGPR (21 months), prolonged time (>5 years) from diagnosis to IRd (20 months), without HRCA (18.6 months). An inferior PFS was seen in lenalidomide-refractory pts (4.8 months). At multivariate analysis using Cox’s regression, the only independent prognostic factors for PFS were age ≥75 (HR 0.35, 95% CI: 0.15-0.82, p=0.016), prolonged time (>5 years) from diagnosis (HR 0.29, 95% CI: 0.13-0.65, p=0.03) and refractoriness to a previous lenalidomide-based treatment (HR 2.23, 95% CI: 1.06-4.70, p=0.035). With regards to survival, lenalidomide-refractory pts had a 2-fold increase in the risk of death (HR 2.1, 95% CI: 0.91-4.8, p=0.08). PFS appears to be superior in the older population possibly related to IRd treatment in earlier lines of therapy (52% of pts aged ≥75 had received IRd after 1 prior line and only 24% after >3 lines); notably, 70% of pts aged ≥75 had HRCA. Summary/Conclusion: In conclusion, in a real-life population with adverse prognostic characteristics in terms of older age, performance status, cytogenetic risk, exposure and refractoriness to lenalidomide, IRd demonstrated inferior OR rates, rates of ≥VGPR and PFS as compared to the pivotal trial, with a good tolerability profile and no new safety concerns. Favorable PFS outcomes, however, emerged for pts achieving at least a VGPR, with 1 prior line of therapy, prolonged time from diagnosis to IRd, and aged ≥75. Moreover, as emerged from the analysis of the elderly population, treatment with IRd in earlier lines of therapy might overcome the adverse impact of high risk cytogenetics. IRd might, therefore, represent an effective and safe combination in selected RRMM pts with an indolent disease course in early lines of treatment, independent of age. Keywords: Real world data, relapsed/refractory, Multiple myeloma" @default.
• W4385667512 created "2023-08-09" @default.
• W4385667512 creator A5004681427 @default.
• W4385667512 creator A5008693201 @default.
• W4385667512 creator A5018088896 @default.
• W4385667512 creator A5019076398 @default.
• W4385667512 creator A5022660132 @default.
• W4385667512 creator A5026829269 @default.
• W4385667512 creator A5031900268 @default.
• W4385667512 creator A5031992080 @default.
• W4385667512 creator A5037700899 @default.
• W4385667512 creator A5044763057 @default.
• W4385667512 creator A5054193089 @default.
• W4385667512 creator A5057333997 @default.
• W4385667512 creator A5061176374 @default.
• W4385667512 creator A5066814162 @default.
• W4385667512 creator A5071417198 @default.
• W4385667512 creator A5079827760 @default.
• W4385667512 creator A5079910766 @default.
• W4385667512 creator A5084302461 @default.
• W4385667512 creator A5086068112 @default.
• W4385667512 creator A5087920510 @default.
• W4385667512 date "2023-08-01" @default.
• W4385667512 modified "2023-09-27" @default.
• W4385667512 title "P970: A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE" @default.
• W4385667512 doi "https://doi.org/10.1097/01.hs9.0000970784.08128.cd" @default.
• W4385667512 hasPublicationYear "2023" @default.
• W4385667512 type Work @default.
• W4385667512 citedByCount "0" @default.
• W4385667512 crossrefType "journal-article" @default.
• W4385667512 hasAuthorship W4385667512A5004681427 @default.
• W4385667512 hasAuthorship W4385667512A5008693201 @default.
• W4385667512 hasAuthorship W4385667512A5018088896 @default.
• W4385667512 hasAuthorship W4385667512A5019076398 @default.
• W4385667512 hasAuthorship W4385667512A5022660132 @default.
• W4385667512 hasAuthorship W4385667512A5026829269 @default.
• W4385667512 hasAuthorship W4385667512A5031900268 @default.
• W4385667512 hasAuthorship W4385667512A5031992080 @default.
• W4385667512 hasAuthorship W4385667512A5037700899 @default.
• W4385667512 hasAuthorship W4385667512A5044763057 @default.
• W4385667512 hasAuthorship W4385667512A5054193089 @default.
• W4385667512 hasAuthorship W4385667512A5057333997 @default.
• W4385667512 hasAuthorship W4385667512A5061176374 @default.
• W4385667512 hasAuthorship W4385667512A5066814162 @default.
• W4385667512 hasAuthorship W4385667512A5071417198 @default.
• W4385667512 hasAuthorship W4385667512A5079827760 @default.
• W4385667512 hasAuthorship W4385667512A5079910766 @default.
• W4385667512 hasAuthorship W4385667512A5084302461 @default.
• W4385667512 hasAuthorship W4385667512A5086068112 @default.
• W4385667512 hasAuthorship W4385667512A5087920510 @default.
• W4385667512 hasBestOaLocation W43856675121 @default.
• W4385667512 hasConcept C126322002 @default.
• W4385667512 hasConcept C141071460 @default.
• W4385667512 hasConcept C197934379 @default.
• W4385667512 hasConcept C207103383 @default.
• W4385667512 hasConcept C2776063141 @default.
• W4385667512 hasConcept C2776364478 @default.
• W4385667512 hasConcept C2777063308 @default.
• W4385667512 hasConcept C2779609412 @default.
• W4385667512 hasConcept C2780108899 @default.
• W4385667512 hasConcept C2780401358 @default.
• W4385667512 hasConcept C2781098529 @default.
• W4385667512 hasConcept C29730261 @default.
• W4385667512 hasConcept C44249647 @default.
• W4385667512 hasConcept C71924100 @default.
• W4385667512 hasConceptScore W4385667512C126322002 @default.
• W4385667512 hasConceptScore W4385667512C141071460 @default.
• W4385667512 hasConceptScore W4385667512C197934379 @default.
• W4385667512 hasConceptScore W4385667512C207103383 @default.
• W4385667512 hasConceptScore W4385667512C2776063141 @default.
• W4385667512 hasConceptScore W4385667512C2776364478 @default.
• W4385667512 hasConceptScore W4385667512C2777063308 @default.
• W4385667512 hasConceptScore W4385667512C2779609412 @default.
• W4385667512 hasConceptScore W4385667512C2780108899 @default.
• W4385667512 hasConceptScore W4385667512C2780401358 @default.
• W4385667512 hasConceptScore W4385667512C2781098529 @default.
• W4385667512 hasConceptScore W4385667512C29730261 @default.
• W4385667512 hasConceptScore W4385667512C44249647 @default.
• W4385667512 hasConceptScore W4385667512C71924100 @default.
• W4385667512 hasIssue "S3" @default.
• W4385667512 hasLocation W43856675121 @default.
• W4385667512 hasLocation W43856675122 @default.
• W4385667512 hasOpenAccess W4385667512 @default.
• W4385667512 hasPrimaryLocation W43856675121 @default.
• W4385667512 hasRelatedWork W1699374300 @default.
• W4385667512 hasRelatedWork W1988784378 @default.
• W4385667512 hasRelatedWork W2034815165 @default.
• W4385667512 hasRelatedWork W2074205062 @default.
• W4385667512 hasRelatedWork W2090603150 @default.
• W4385667512 hasRelatedWork W2192430028 @default.
• W4385667512 hasRelatedWork W2345487218 @default.
• W4385667512 hasRelatedWork W2378175831 @default.
• W4385667512 hasRelatedWork W2430400806 @default.
• W4385667512 hasRelatedWork W3027894540 @default.
• W4385667512 hasVolume "7" @default.
• W4385667512 isParatext "false" @default.
• W4385667512 isRetracted "false" @default.
• W4385667512 workType "article" @default.